Evidence map›Paper›PMID 30328096›Full record

ArticleHealth services research2019

Risk equalization in competitive health insurance markets: Identifying healthy individuals on the basis of multiple-year low spending.

Frank Eijkenaar, René C J A van Vliet, Richard C van Kleef

Abstract read
In one paragraph

Article in Health services research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Frank EijkenaarErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-4471-7623
René C J A van VlietErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Richard C van KleefErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

Funding

Ministerie van Volksgezondheid, Welzijn en Sport
6 · The paper itself

Abstract

objectiveTo study the extent to which risk equalization (RE) in competitive health insurance markets can be improved by including an indicator for being healthy. STUDY SETTING/DATA SOURCES: This study is conducted in the context of the Dutch individual health insurance market. Administrative data on spending and risk characteristics (2011-2014) for the entire population (N = 16.6 m) as well as health survey data from a large sample (N = 387 k) are used. STUDY

designThe indicator for being healthy is low spending in three consecutive prior years. "Low spending" is defined in three ways: belonging to the bottom 60%, 70%, or 80% of the annual spending distribution. Versions of the Dutch RE model 2017 with and without the indicator are compared on individual-level payment fit and, using the survey data, group-level payment fit. PRINCIPAL

findingsAll three alternative models outperform the Dutch RE model 2017. However, significant unpriced risk heterogeneity remains. Compared with the 60% threshold, the 80% threshold comes with a larger improvement in fit but identifies a less selective group.

conclusionsThe performance of the RE model can be improved by adding an indicator for being healthy based on multiple-year low spending. However, risk-selection potential remains, warranting high priority to further improvement of RE.

Indexed as

Financing, PersonalHealth ExpendituresHealth StatusHospitalizationHumansInsurance, HealthMental Health ServicesModels, EconomicNetherlandsPrescription DrugsRisk AdjustmentRisk FactorsPrescription Drugshealth insurancehealth measurementrisk equalizationspendingsurvey data

Identifiers

PMID30328096
PMCPMC6407341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.